PCM
RNAC icon

Proxima Capital Management’s Cartesian Therapeutics RNAC Stock Holding History

Proxima Capital Management’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-1,000
Closed -$53K – 28
2019
Q3 		$53K Sell
1,000
-377
-27% -$20K 0.08% 30
2019
Q2 		$74K Sell
1,377
-666
-33% -$45.4K 0.1% 30
2019
Q1 		$145K Hold
2,043
– – 0.16% 34
2018
Q4 		$163K Sell
2,043
-207
-9% -$47.2K 0.15% 36
2018
Q3 		$1.05M Sell
2,250
-453
-17% -$182K 0.7% 29
2018
Q2 		$1.07M Buy
+2,703
New +$959K 0.64% 28

Other funds holding RNAC

MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Proxima Capital Management's RNAC Position: Q4 2019 in Review

Proxima Capital Management sold out of Cartesian Therapeutics (RNAC) in Q4 2019, closing a stake of 1,000 shares — an estimated $53K sold.

Proxima Capital Management first reported a position in RNAC in Q2 2018 and held it in 6 quarters. The position peaked at $1.07M in Q2 2018. 38 funds tracked by Wall St. Rank hold RNAC as of Q4 2019.

  • Proxima Capital Management reported no remaining Cartesian Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Proxima Capital Management sold 1,000 Cartesian Therapeutics shares in Q4 2019, an estimated $53K.
  • Proxima Capital Management first reported a position in Cartesian Therapeutics in Q2 2018 and held it in 6 quarters.
  • Proxima Capital Management's Cartesian Therapeutics position peaked at $1.07M in Q2 2018.
  • 38 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q4 2019.

Based on Proxima Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.